Mannatech, Inc. Stock Plummets to New 52-Week Low of $6.59

Mannatech, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 6.59 as of March 4, 2026. This decline marks a significant downturn for the company, which has seen its stock price decrease by 15.65% over the past year, contrasting sharply with the S&P 500's performance of 17.36% during the same period. The company's financial metrics reveal a challenging landscape. Mannatech's market capitalization stands at USD 19 million, and it currently operates at a loss, reflected in its negative price-to-earnings ratio. The return on equity is notably low at -23.83%, indicating difficulties in generating profit from shareholder equity. Additionally, the company has a debt-to-equity ratio of -0.40, suggesting a complex financial structure. Institutional investor participation has also waned, with a 10.19% reduction in stakes over the last quarter, leaving them with a collective holding of just 12.16%. This trend, combined with a significant drop in net profit and cash reserves, underscores the challenges facing Mannatech as it navigates a competitive market.